OKYO Stock Price, Analysis & Fundamentals

Analysis

OKYO Pharma Limited is a biotechnology company in the healthcare sector. With a market capitalization of $90.27 million, it operates on a relatively small scale, employing only 4 individuals. The financial performance of OKYO Pharma Limited is characterized by significant losses. The net income over the trailing twelve months (TTM) amounts to -$4,706,292, while EBITDA stands at -$7,089,334. Furthermore, free cash flow is negative at -$2,723,457. Despite these substantial losses, the company maintains a cash position of $1.56 million. However, specific debt levels are not provided. OKYO Pharma Limited's valuation metrics indicate a complex situation. The price to book ratio is -15.58, and the EV/EBITDA ratio is -11.61. These numbers do not provide clear indicators for evaluating the company's worth.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About OKYO Pharma Limited

OKYO Pharma Limited, a clinical-stage biopharmaceutical company, develops therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase II clinical trials for the treatment of dry eye disease; in Phase II clinical trial to treat neuropathic corneal pain; and is in preclinical trial to treat allergic conjunctivitis and uveitis. The company is also developing OK-201 for the treatment acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

Visit website →

OKYO

Price History (1Y)

Analysis

About OKYO Pharma Limited

Key Statistics

Company Info